Prognostic information derived from RT-PCR analysis of peritoneal fluid in gastric cancer patients: Results from a prospective multicenter clinical trial

2013 ◽  
Vol 109 (2) ◽  
pp. 75-80 ◽  
Author(s):  
Shigeyuki Tamura ◽  
Yoshiyuki Fujiwara ◽  
Yutaka Kimura ◽  
Junya Fujita ◽  
Hiroshi Imamura ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Cancer Patients ◽  
Peritoneal Fluid ◽  
Pcr Analysis ◽  
Multicenter Clinical Trial ◽  
Rt Pcr ◽  
Prognostic Information ◽  
Gastric Cancer Patients

Phase II Clinical Trial of Postoperative S-1 Monotherapy for Gastric Cancer Patients with Free Intraperitoneal Cancer Cells Detected by Real-Time RT-PCR

2010 ◽  
Vol 34 (9) ◽  
pp. 2083-2089 ◽  
Author(s):  
Seiji Ito ◽  
Yasuhiro Kodera ◽  
Yoshinari Mochizuki ◽  
Taiki Kojima ◽  
Hayao Nakanishi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Cancer Cells ◽  
Real Time ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Rt Pcr ◽  
Gastric Cancer Patients

scholarly journals UHPLC-ESI-MS/MS Quantification of Relevant Substrates and Metabolites of the Kynurenine Pathway Present in Serum and Peritoneal Fluid from Gastric Cancer Patients—Method Development and Validation

2021 ◽  
Vol 22 (13) ◽  
pp. 6972
Author(s):  
Ilona Sadok ◽  
Katarzyna Jędruchniewicz ◽  
Karol Rawicz-Pruszyński ◽  
Magdalena Staniszewska
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Peritoneal Fluid ◽  
Method Development ◽  
Solid Phase ◽  
Kynurenine Pathway ◽  
Serum Samples ◽  
Esi Ms ◽  
Gastric Cancer Patients ◽  
Development And Validation

Metabolites and enzymes involved in the kynurenine pathway (KP) are highly promising targets for cancer treatment, including gastrointestinal tract diseases. Thus, accurate quantification of these compounds in body fluids becomes increasingly important. The aim of this study was the development and validation of the UHPLC-ESI-MS/MS methods for targeted quantification of biologically important KP substrates (tryptophan and nicotinamide) and metabolites(kynurenines) in samples of serum and peritoneal fluid from gastric cancer patients. The serum samples were simply pretreated with trichloroacetic acid to precipitate proteins. The peritoneal fluid was purified by solid-phase extraction before analysis. Validation was carried out for both matrices independently. Analysis of the samples from gastric cancer patients showed different accumulations of tryptophan and its metabolites in different biofluids of the same patient. The protocols will be used for the evaluation of tryptophan and kynurenines in blood and peritoneal fluid to determine correlation with the clinicopathological status of gastric cancer or the disease’s prognosis.

scholarly journals Effects of perioperative ERAS pathway management VS traditional management on clinical outcomes in laparoscopic-assisted radical resection of distal gastric cancer The GISSG18-01 Randomized Clinical Trial

2020 ◽  
Author(s):  
Yulong Tian ◽  
Shougen Cao ◽  
Leping Li ◽  
Qingsi He ◽  
Lijian Xia ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Cancer Patients ◽  
Radical Resection ◽  
Control Group ◽  
Short Term ◽  
Traditional Management ◽  
Gastric Cancer Patients ◽  
Laparoscopic Assisted ◽  
Experimental Group

Abstract Background: As well known, the incidence of gastric cancer in East Asian countries is much higher than the international average. Therefore, improving the prognosis of patients and establishing effective clinical pathways are important topics for the prevention and treatment of gastric cancer. At present, the enhanced recovery after surgery (ERAS) pathway is widely used in the field of gastric surgery. Many RCT studies have proven that the ERAS regimen can not improve the short-term clinical outcomes of gastric cancer patients. However, a prospective study on the effect of the ERAS pathway on the prognosis of gastric cancer patients has not been reported. This trial aims to confirm whether ERAS pathway can improve disease-free survival (DFS) and overall survival (OS) in patients undergoing laparoscopic-assisted radical resection for distal gastric cancer.Methods/design: This study is a prospective, multicenter, randomized controlled trial (RCT). This experiment will include randomly divided groups, the experimental group and the control group, according to a proportion of 1:1. The perioperative period of the experimental group will be managed according to the ERAS pathway, and the control group will be managed according to the traditional management mode. An estimated 400 patients will be enrolled. The main endpoint is to compare the 3-year OS and PFS between the two groups.Discussion: This RCT should demonstrate whether ERAS pathway is superior to traditional treatment on inflammatory indexes, short-term clinical outcome and survival for laparoscopic assisted radical resection of distal gastric cancer.Our data can provide evidence that the ERAS pathway improves survival in patients with gastric cancer.Trial registration: Chinese Clinical Trial Registry, CHiCTR1900022438. Registered on 11 April 2019

Sign in / Sign up

Export Citation Format

Share Document